Composition of curcumagalactomannoside and hops extract
A composition for treatment of inflammation in a mammal is provided. The mammal has a neutrophil to lymphocyte ratio (NLR). The composition includes a curcumagalactomannoside and a hops extract. The curcumagalactomannoside and the hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition. A method of treatment of inflammation in a mammal is also provided. The method includes obtaining a parameter of the mammal. The method further includes dosing the composition based on the parameter. The method further includes administering the composition to the mammal.
1. A composition for treatment of inflammation in a mammal, the mammal having a neutrophil to lymphocyte ratio (NLR), the composition comprising:
a curcumagalactomannoside; and
a hops extract;
wherein the curcumagalactomannoside and the hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition.
2. The composition of claim 1 , wherein the curcumagalactomannoside is derived from a curcuminoid and a galactomannan.
3. The composition of claim 2 , wherein the curcuminoid is present in the curcumagalactomannoside in an amount of from about 20 wt. % to about 60 wt. % based on a total weight of the curcumagalactomannoside.
4. The composition of claim 1 , wherein the curcumagalactomannoside is present in the composition in an amount of from about 0.01 wt. % to about 10 wt. % based on a total weight of the composition.
5. The composition of claim 1 , wherein the hops extract comprises xanthohumol.
6. The composition of claim 1 , comprising a protein-containing matrix, the protein-containing matrix comprising the hops extract.
7. The composition of claim 6 , wherein the hops extract is present in the protein-containing matrix in an amount of from about 1 wt. % to about 95 wt. % based on a total weight of the protein-containing matrix.
8. The composition of claim 1 , wherein the hops extract is present in the composition in an amount of from about 0.01 wt. % to about 10 wt. % based on a total weight of the composition.
9. The composition of claim 1 , further comprising a ginger root extract.
10. The composition of claim 9 , wherein the ginger root extract comprises a pungent compound in an amount of from about 0.1 wt. % to about 20 wt. % based on a total weight of the ginger root extract.
11. The composition of claim 1 , further comprising aquercetin, rosemary extract, folate, vitamin B-12, or combinations thereof.
12. The composition of claim 1 , further comprising an amino acid, a peptide, a protein, a lipid, a vitamin, a carbohydrate, a nucleic acid, a mineral, an anabolic nutrient, an antioxidant, a probiotic bacterial strain, a lipotropic agent, a flavoring agent, a dye, a flow modifier, a preservative, a filler, a binder, a dispersing agent, a human milk oligosaccharide, isomalto-oligosaccharide, a fiber, or combinations thereof.
13. The composition of claim 12 , wherein the amino acid is present and the amino acid is selected from the group consisting of L-lysine, L-leucine, L-glutamine, L-valine, L-isoleucine, and combinations thereof.
14. A composition for treatment of inflammation in a mammal, the mammal having a neutrophil to lymphocyte ratio (NLR), the composition consisting essentially of:
curcumagalactomannoside;
a hops extract;
a ginger root extract;
a protein-containing matrix;
a rosemary leaf extract;
folate;
vitamin B-12; and
quercetin;
wherein at least the curcumagalactomannoside and hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition.
15. A composition for treatment of inflammation in a mammal, the mammal having a neutrophil to lymphocyte ratio (NLR), the composition comprising:
a curcumagalactomannoside; and
a protein-containing matrix;
wherein the protein-containing matrix comprises a hops extract; and
wherein the curcumagalactomannoside and the hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition;
optionally, wherein the hops extract is present in the protein-containing matrix in an amount of from about 1 wt. % to about 95 wt. % based on a total weight of the protein-containing matrix.
16. The composition of claim 15 , wherein the curcumagalactomannoside is derived from a curcuminoid and a galactomannan, optionally wherein the curcuminoid is present in the curcumagalactomannoside in an amount of from about 20 wt. % to about 60 wt. % based on a total weight of the curcumagalactomannoside.
17. The composition according to claim 15 , wherein the hops extract is present in the protein-containing matrix in an amount of from about 1 wt. % to about 95 wt. % based on a total weight of the protein-containing matrix.
18. The composition of claim 17 , wherein:
i) the curcumagalactomannoside is present in the composition in an amount of from about 0.01 wt. % to about 10 wt. % based on a total weight of the composition; and
ii) the hops extract is present in the composition in an amount of from about 0.01 wt. % to about 10 wt. % based on a total weight of the composition.